Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Phase 3 Trial of Secukinumab in Polymyalgia Rheumatica.

The New England journal of medicine·2026
Same author

Subtype-specific mortality in idiopathic inflammatory myopathies: A hospital-based cohort.

Autoimmunity reviews·2026
Same author

Health-related quality of life in French adults with X-linked hypophosphatemia: real-world data from the International XLH Registry.

JBMR plus·2026
Same author

Reliability of ultrasound assessment of elementary lesions in psoriatic arthritis and development of a reference dactylitis atlas.

Rheumatology (Oxford, England)·2026
Same author

Time and patient journey to axial spondyloarthritis diagnosis: a retrospective study in French primary care.

Rheumatology (Oxford, England)·2026
Same author

Further Validation of a Questionnaire to Assess Flare in Psoriatic Arthritis: Determination of Cutoff and Longitudinal Change.

The Journal of rheumatology·2026

Related Experiment Video

Updated: Sep 20, 2025

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients
02:28

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients

Published on: March 1, 2024

506

Increased Cardiovascular Risk in Psoriatic Arthritis: Results From a Case-Control Monocentric Study.

Yannick Degboé1, Richard Koch1, Laurent Zabraniecki1

  • 1Department of Rheumatology, Toulouse University Hospital and University Toulouse III, Toulouse, France.

Frontiers in Medicine
|June 6, 2022
PubMed
Summary
This summary is machine-generated.

Patients with psoriatic arthritis (PsA) have more cardiovascular risk factors and events than the general population. Standard risk scores underestimate cardiovascular risk in PsA, highlighting the need for adjusted assessments.

Keywords:
cardiovascular eventscardiovascular riskdyslipidaemiapsoriatic arthritisstatins

More Related Videos

Author Spotlight: Assessing the Cardiovascular Profile of Patients with Metabolic Syndrome
06:04

Author Spotlight: Assessing the Cardiovascular Profile of Patients with Metabolic Syndrome

Published on: September 27, 2024

1.1K
Aggravation of Myocardial Ischemia upon Particulate Matter Exposure in Atherosclerosis Animal Model
07:35

Aggravation of Myocardial Ischemia upon Particulate Matter Exposure in Atherosclerosis Animal Model

Published on: December 10, 2021

2.1K

Related Experiment Videos

Last Updated: Sep 20, 2025

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients
02:28

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients

Published on: March 1, 2024

506
Author Spotlight: Assessing the Cardiovascular Profile of Patients with Metabolic Syndrome
06:04

Author Spotlight: Assessing the Cardiovascular Profile of Patients with Metabolic Syndrome

Published on: September 27, 2024

1.1K
Aggravation of Myocardial Ischemia upon Particulate Matter Exposure in Atherosclerosis Animal Model
07:35

Aggravation of Myocardial Ischemia upon Particulate Matter Exposure in Atherosclerosis Animal Model

Published on: December 10, 2021

2.1K

Area of Science:

  • Cardiology
  • Rheumatology
  • Public Health

Background:

  • Psoriatic arthritis (PsA) is linked to increased cardiovascular morbidity and mortality.
  • Understanding cardiovascular risk factors (CVRFs) and events (CVEs) in PsA is crucial for patient management.

Purpose of the Study:

  • Compare CVRFs and CVEs prevalence in PsA versus a control population.
  • Evaluate the impact of adjusted cardiovascular risk (CVR) equations in PsA.
  • Determine LDLc target attainment in PsA patients according to European guidelines.

Main Methods:

  • Observational, cross-sectional, case-control study comparing 207 PsA patients with 414 controls.
  • Systematic assessment of CVRFs, CVEs, and CVR using SCORE and QRISK2 equations.
  • Application of EULAR-recommended adjustments (SCORE-PsA, QRISK2-PsA) for CVR assessment.

Main Results:

  • PsA patients exhibited higher prevalence of CVRFs and CVEs.
  • Atherothrombotic disease was significantly increased in PsA patients (SCORE p=0.002, QRISK2 p=0.001).
  • Adjusted scores (SCORE-PsA, QRISK2-PsA) revealed a higher percentage of PsA patients with elevated CVR.

Conclusions:

  • PsA patients face a greater burden of CVRFs and CVEs compared to the general population.
  • Standard CVR assessment tools underestimate risk in PsA; adjusted scores are more accurate.
  • A significant proportion of PsA patients with high CVR are undertreated with statins.